Kazia Therapeutics Ltd ADR (KZIA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $8.85
• Market Cap: $86.15M
• EPS: $-15.88
• 52-Week High: $17.40
• 52-Week Low: $2.86

Market Sentiment

Kazia Therapeutics Ltd ADR currently has a Bullish sentiment score of 0.43.

About Kazia Therapeutics Ltd ADR

Kazia Therapeutics Ltd ADR is an innovative Australian biotechnology firm based in Sydney, primarily engaged in the development of advanced cancer therapies. The company is advancing its proprietary drug candidates through clinical trials, with a particular focus on addressing significant unmet needs in oncology, including treatments for brain cancer and other solid tumors. Its lead asset, GDC-0084, targets key pathways in cancer biology, aspiring to improve patient outcomes. With a strong co...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Kazia Therapeutics Ltd ADR and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KZIA pay dividends?

Kazia Therapeutics Ltd ADR (KZIA) does not currently pay a regular dividend.

What is KZIA's market cap?

Kazia Therapeutics Ltd ADR (KZIA) has a market capitalization of $86.15M with a current stock price of $8.85.